Kodiak Sciences Inc. (KOD): Cash & Equivalents
$209.86M
As of 2025-12-31
$125.90M
As of 2026-06-30
+3.3%
3-year compound annual growth
-26.0%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $209.86M | +24.9% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $168.07M | -41.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $285.51M | +49.9% | 2026-03-31, Balance as of period end |
| 2022-12-31 | $190.43M | -74.0% | 2025-03-27, Balance as of period end |
| 2021-12-31 | $731.51M | -22.5% | 2024-03-28, Balance as of period end |
| 2020-12-31 | $944.40M | +345.9% | 2023-03-28, Balance as of period end |
| 2019-12-31 | $211.80M | +140.0% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $88.25M | n/m | 2021-03-01, Balance as of period end |
| 2017-12-31 | $1.40M | -85.5% | 2020-03-16, Balance as of period end |
| 2016-12-31 | $9.62M | n/a | 2019-03-27, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $209.86M | +24.9% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $319.77M | +130.0% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $63.03M | -65.5% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| Prokidney Corp. (PROK) | 2025-12-31 | $108.54M | +9.5% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $209.02M | +88.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $46.63M | +29.3% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $189.25M | -3.8% |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗